» Articles » PMID: 17189416

Inhibitory Effects of Castration in an Orthotopic Model of Androgen-independent Prostate Cancer Can Be Mimicked and Enhanced by Angiogenesis Inhibition

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2006 Dec 26
PMID 17189416
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Today, the most important treatment of advanced prostate cancer is castration; unfortunately, however, the long-term effect of this therapy is insufficient. Recent studies suggest that castration-induced prostate involution could be caused by primary effects in the prostate vasculature; therefore, we examined if antivascular treatments could mimic the effects of castration.

Experimental Design: Androgen-independent AT-1 prostate cancer cells were grown inside the ventral prostate in adult rats. Tumor-bearing animals were treated with an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor signaling, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine (ZD6474, AstraZeneca, Södertälje, Sweden), and short-term effects (after 3 days) were compared with those induced by castration.

Results: Castration caused decreased vascular density in the normal tissue surrounding the tumor and consequently increased tumor hypoxia and apoptosis, and moderately decreased tumor growth. ZD6474 treatment resulted in decreased tumor vascular density accompanied by increased tumor hypoxia, apoptosis, and decreased tumor growth, suggesting that castration and antiangiogenic therapy work through similar mechanisms. Interestingly, castration or ZD6474 alone worked by reducing vascular density in the surrounding normal tissue and ZD6474 also in the tumor. Combined treatment with castration + ZD6474 was more effective than castration and ZD6474 alone in inducing tumor hypoxia, apoptosis, necrosis, and decreasing tumor vascular density.

Conclusion: These findings show that a drug that targets the vasculature in the tumor and in the surrounding ventral prostate lobe could mimic and even enhance the effects of castration. Our present findings thus suggest that castration + ZD6474 could be a particularly effective way to treat prostate tumors.

Citing Articles

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.

Guerin O, Fischel J, Ferrero J, Bozec A, Milano G Pharmaceuticals (Basel). 2016; 3(7):2238-2247.

PMID: 27713352 PMC: 4036653. DOI: 10.3390/ph3072238.


Extratumoral Heme Oxygenase-1 (HO-1) Expressing Macrophages Likely Promote Primary and Metastatic Prostate Tumor Growth.

Bergstrom S, Nilsson M, Adamo H, Thysell E, Jernberg E, Stattin P PLoS One. 2016; 11(6):e0157280.

PMID: 27280718 PMC: 4900522. DOI: 10.1371/journal.pone.0157280.


Adaptive (TINT) Changes in the Tumor Bearing Organ Are Related to Prostate Tumor Size and Aggressiveness.

Adamo H, Stromvall K, Nilsson M, Bergstrom S, Bergh A PLoS One. 2015; 10(11):e0141601.

PMID: 26536349 PMC: 4633147. DOI: 10.1371/journal.pone.0141601.


High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting.

Nilsson M, Hagglof C, Hammarsten P, Thysell E, Stattin P, Egevad L PLoS One. 2015; 10(10):e0140985.

PMID: 26501565 PMC: 4621025. DOI: 10.1371/journal.pone.0140985.


Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.

Kalmuk J, Folaron M, Buchinger J, Pili R, Seshadri M Oncotarget. 2015; 6(27):24376-92.

PMID: 26203773 PMC: 4695192. DOI: 10.18632/oncotarget.4463.